Supporting this model, a 2020 study demonstrated impaired glucagon-mediated amino acid turnover in the liver of individuals with obesity and NAFLD compared to lean, non-steatotic controls [30]. Here, GCG is linked to metabolic dysfunction-associated steatotic liver disease.